Vernalis plc (LON:VER) released its earnings results on Tuesday. The company reported GBX (4.10) (($0.05)) EPS for the quarter, topping analysts’ consensus estimates of GBX (4.50) (($0.06)) by GBX 0.40 ($0.01), Digital Look Earnings reports. Vernalis plc had a negative net margin of 198.87% and a negative return on equity of 22.58%. The business had revenue of GBX 207.90 billion for the quarter.
Vernalis plc (LON VER) traded up 0.000% on Thursday, hitting GBX 15.625. 27,100 shares of the stock traded hands. The company’s 50 day moving average price is GBX 16.74 and its 200-day moving average price is GBX 19.62. The stock’s market capitalization is GBX 82.24 million. Vernalis plc has a 12-month low of GBX 15.00 and a 12-month high of GBX 45.13.
VER has been the topic of a number of research reports. N+1 Singer reiterated a “hold” rating and issued a GBX 28 ($0.36) target price on shares of Vernalis plc in a report on Monday, August 7th. RX Securities reiterated a “buy” rating on shares of Vernalis plc in a report on Monday, August 7th. Panmure Gordon reiterated a “hold” rating and issued a GBX 31 ($0.40) target price on shares of Vernalis plc in a report on Monday, August 7th. Finally, Stifel Nicolaus dropped their target price on shares of Vernalis plc from GBX 24 ($0.31) to GBX 21 ($0.27) and set a “hold” rating on the stock in a research report on Monday, August 7th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 39.40 ($0.51).
About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.